Page last updated: 2024-10-17

3,4-dihydroxyphenylacetic acid and Bradykinesia

3,4-dihydroxyphenylacetic acid has been researched along with Bradykinesia in 6 studies

3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.

Research Excerpts

ExcerptRelevanceReference
" Behavioral deficits at the end of the 14-day dosing regime and on day 28 (i."1.40Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates. ( Davydova, TV; Fomina, VG; Gruden, MA; Kudrin, VS; Morozova-Roche, LA; Narkevich, VB; Sewell, RD; Wang, C, 2014)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gruden, MA1
Davydova, TV1
Narkevich, VB1
Fomina, VG1
Wang, C1
Kudrin, VS1
Morozova-Roche, LA1
Sewell, RD1
Sgadò, P1
Viaggi, C1
Pinna, A1
Marrone, C1
Vaglini, F1
Pontis, S1
Mercuri, NB1
Morelli, M1
Corsini, GU1
Bajo-Grañeras, R1
Ganfornina, MD1
Martín-Tejedor, E1
Sanchez, D1
Dhanushkodi, A1
Akano, EO1
Roguski, EE1
Xue, Y1
Rao, SK1
Matta, SG1
Rex, TS1
McDonald, MP1
Hantraye, P1
Brouillet, E1
Ferrante, R1
Palfi, S1
Dolan, R1
Matthews, RT1
Beal, MF1
Abe, K1
Taguchi, K1
Wasai, T1
Ren, J1
Utsunomiya, I1
Shinohara, T1
Miyatake, T1
Sano, T1

Other Studies

6 other studies available for 3,4-dihydroxyphenylacetic acid and Bradykinesia

ArticleYear
Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.
    Behavioural brain research, 2014, Apr-15, Volume: 263

    Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; alpha-Synuclein; Amyloid; Animals; Corpu

2014
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration.
    Neurotoxicity research, 2011, Volume: 20, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Analysis of Variance; Animals; Behavior, Animal; Brain

2011
Apolipoprotein D mediates autocrine protection of astrocytes and controls their reactivity level, contributing to the functional maintenance of paraquat-challenged dopaminergic systems.
    Glia, 2011, Volume: 59, Issue:10

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Apolipoproteins D; Apoptosis; Astrocytes;

2011
A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism.
    Genes, brain, and behavior, 2013, Volume: 12, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dependovirus; Dopamine; Erythropoietin; Ge

2013
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
    Nature medicine, 1996, Volume: 2, Issue:9

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model

1996
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
    Brain research bulletin, 2001, Sep-01, Volume: 56, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Do

2001